8-K current report · filed Jul 8, 2026

Azenta, Inc. (AZTA) 8-K Current Report: July 8, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 1.01Item 2.01AZTA overview

Short answer

Azenta, Inc. (AZTA) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets). $35 million vendor loan funded to facilitate Azenta’s acquisition of B Medical Systems.

Azenta, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $35 million vendor loan funded to facilitate Azenta’s acquisition of B Medical Systems
  • 6.0% interest rate, three-month maturity, full repayment required at maturity
  • First-priority pledge over 100% of B Medical Systems equity secures Thelema’s obligations
  • Related-party transaction, as Thelema is majority owned by Azenta executive Luc Provost
  • Security may be subordinated or released for acquisition financing or refinancing, increasing repayment risk

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Azenta completed the B Medical Systems sale on July 1, 2026, transferring the entire business to Thelema
  • Fixed transaction value of $63 million, comprising $28 million cash and a $35 million vendor loan
  • Cash proceeds provide near-term liquidity, while the vendor loan creates repayment exposure to Azenta
  • Delayed closing from March 31 to July 1 reflects prior buyer financing constraints, now resolved

Item 7.01 · Regulation FD Disclosure

  • Azenta announced completion of the Transaction on July 8, 2026
  • Transaction completion marks the closing of a previously disclosed corporate event
  • Exhibit 99.1 contains the press release with transaction details

Item EX-99.1 · Exhibit EX-99.1

  • Azenta completed the B Medical Systems sale to Thelema on July 1, 2026
  • Fixed purchase price $63 million in cash, including $35 million funded through Azenta’s secured vendor loan
  • Portfolio simplification toward core life sciences businesses, with proceeds intended to improve financial flexibility
  • Vendor-loan repayment depends on Thelema’s third-party financing, creating counterparty default risk for Azenta

Item EX-99.2 · Exhibit EX-99.2

  • B Medical sale completed July 1, 2026 for $63.0M cash consideration, simplifying Azenta’s portfolio through a significant disposition
  • $28.0M total cash received, including $19.0M at closing and a $35.0M related-party note receivable
  • Vendor loan secured by B Medical, bearing 6.0% interest and maturing three months after funding, creating near-term repayment exposure
  • Pro forma assets decline $91.6M to $1.812B, while liabilities fall $50.1M to $299.1M
  • Retained earnings decrease $41.5M from $46.9M cumulative translation adjustments, partially offset by $5.4M estimated selling costs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Azenta, Inc. 8-K filings

Get the next AZTA 8-K as it lands

Follow AZTA for push alerts, or ask the research agent what this filing means.